Teva Pharmaceutical Industries

Amneal to introduce US generic Byetta, first GLP-1 agonist to receive FDA approval, following Teva's withdrawal.

Converge Bio, a generative AI hub for Biotech and Pharma, raised $5.5 million in seed funding led by TLV Partners. The platform accelerates drug discovery and development using large language models (LLMs), offering services like engineering antibodies and designing mRNA vaccines. Partners include Teva, Compugen, and BiomX. Converge Bio aims to expand its AI capabilities with the new funds.

The EC fined Teva €462.6 million for abusing its dominant position to delay competition to Copaxone, marking the first time a pharma company was held liable for 'exclusionary disparagement.' This decision highlights the rising tide of antitrust enforcement against disparagement practices in the pharma sector, raising questions about the boundary between legitimate competition and illegal means.

Teva Pharmaceuticals and AI-driven Immunai partner to optimize immunology and immuno-oncology clinical trials using Immunai’s immune cell atlas, AMICA, and AI model, IDE. Focus areas include drug mechanism of action, dose selection, and biomarker analyses, with potential expansion to broader R&D aspects.

Elite Pharmaceuticals Inc. reported a 33% revenue increase to $18.9 million in Q2 FY2025, with year-to-date revenues up 63% to $37.7 million. Operating income doubled to $3.5 million, and cash flow turned positive at $4.6 million. The company launched new products and anticipates significant ANDA approvals, projecting record revenues of $56 million for FY2024. Despite increased liabilities, the company maintains a strong cash position and robust pipeline, expressing confidence in future growth.

The article discusses the importance of enabling JavaScript for optimal app performance.

Immunai and Teva initiate multi-year AI collaboration to advance drug development using Immunai’s immune system mapping tools for precision in immunology and oncology trials.

FDA accepts Organon's aBLA for HLX14, a Prolia®/Xgeva® biosimilar, and Teva's application for its Prolia® biosimilar TVB-009P. Litigations continue between Amgen and biosimilar developers Celltrion, Samsung Bioepis, and Fresenius Kabi. Sandoz's Jubbonti®/Wyost® was approved as interchangeable with Prolia®/Xgeva®.

Teva sued Deva for patent infringement of ProAir® HFA patents listed in the FDA’s Orange Book. Deva moved to dismiss, arguing no infringement under 35 U.S.C. § 271(e) and lack of immediacy for declaratory judgment. The court denied-in-part, finding sufficient facts for declaratory judgment, and reserved-in-part pending appeal in Teva v. Amneal.